Rescue therapy with tacrolimus is effective in patients with severe and refractory inflammatory bowel disease
Open Access
- 16 May 2003
- journal article
- research article
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 17 (10), 1273-1281
- https://doi.org/10.1046/j.1365-2036.2003.01534.x
Abstract
Background : Oral tacrolimus, approved for the prophylaxis of organ rejection in liver or kidney transplants, has been reported to be effective in anecdotal cases of refractory inflammatory bowel disease. Aim : To evaluate the usefulness of low‐dose oral tacrolimus in refractory inflammatory bowel disease. Methods: Thirty‐one adult Caucasian patients with steroid‐dependent (n = 15) or steroid‐refractory (n = 16) inflammatory bowel disease (Crohn's disease, n = 6; ulcerative colitis, n = 23; pouchitis, n = 2) were enrolled. Tacrolimus (0.1 mg/kg body weight per day) was administered orally in 30 patients and initially intravenously in one patient (0.01 mg/kg body weight per day), aiming for serum trough levels of 4–6 ng/mL. The median treatment duration was 12 months (range, 1–137 months). Results : Twenty‐eight patients (90.3%) experienced a clinical and laboratory response and 20 (64.5%) went into remission. One ulcerative colitis patient and two Crohn's disease patients did not improve. Three ulcerative colitis patients (9.7%) were colectomized at 1, 12 and 24 months after tacrolimus initiation. In 19 of 23 patients (82.6%) taking steroids, steroids were reduced or discontinued. Side‐effects included a temporary rise of creatinine (n = 3, 9.7%), tremor or paraesthesias (n = 3, 9.7%), hyperkalaemia (n = 1, 3.2%), hypertension (n = 1, 3.2%) and an opportunistic infection (n = 1, 3.2%). Conclusion : Oral tacrolimus is safe and effective in refractory inflammatory bowel disease.Keywords
This publication has 39 references indexed in Scilit:
- Evolving Treatment Strategies for Inflammatory Bowel DiseaseAnnual Review of Medicine, 2001
- Pharmacokinetics of Cyclosporin Microemulsion in Patients with Inflammatory Bowel DiseaseClinical Pharmacokinetics, 2001
- Topical tacrolimus may be effective in the treatment of oral and perineal Crohn's diseaseGut, 2000
- Characterization of Calcineurin in Human NeutrophilsPublished by Elsevier BV ,1999
- Effects of FK506 on an experimental model of colitis in ratsAlimentary Pharmacology & Therapeutics, 1995
- Activated Immunocompetent Cells in Rat Colitis Mucosa Induced by Dextran Sulfate Sodium and Not Complete but Partial Suppression of Colitis by FK506Digestion, 1995
- Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejectionThe Lancet, 1994
- Frequency of glucocorticoid resistance and dependency in Crohn's disease.Gut, 1994
- TacrolimusDrugs, 1993
- High-Dose Methylprednisolone in the Treatment of Active Ulcerative ColitisJournal of Clinical Gastroenterology, 1990